Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus PT from Analysts

Precigen, Inc. (NASDAQ:PGEN) has been given an average recommendation of “Moderate Buy” by the five analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $7.00.

Several equities research analysts recently weighed in on PGEN shares. JMP Securities decreased their target price on Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a research note on Thursday, August 15th. StockNews.com upgraded shares of Precigen to a “sell” rating in a report on Thursday, August 1st. Finally, HC Wainwright cut their price target on shares of Precigen from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th.

Precigen Trading Up 4.2 %

Shares of NASDAQ:PGEN opened at $0.95 on Friday. Precigen has a 52 week low of $0.82 and a 52 week high of $1.93. The company’s 50 day moving average is $1.00 and its two-hundred day moving average is $1.31. The company has a market cap of $240.91 million, a PE ratio of -1.76 and a beta of 1.66.

Precigen (NASDAQ:PGEN) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $1.28 million. Precigen had a negative net margin of 3,084.55% and a negative return on equity of 90.99%. As a group, equities research analysts expect that Precigen will post -0.44 EPS for the current year.

Insider Transactions at Precigen

In other Precigen news, SVP Jeffrey Thomas Perez purchased 58,823 shares of Precigen stock in a transaction that occurred on Friday, August 9th. The stock was purchased at an average price of $0.85 per share, for a total transaction of $49,999.55. Following the transaction, the senior vice president now directly owns 743,097 shares in the company, valued at $631,632.45. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 44.90% of the company’s stock.

Hedge Funds Weigh In On Precigen

Several institutional investors have recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC acquired a new position in shares of Precigen in the first quarter valued at approximately $1,022,000. EntryPoint Capital LLC acquired a new position in Precigen in the 1st quarter valued at $31,000. Vanguard Group Inc. raised its position in Precigen by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after buying an additional 19,875 shares during the last quarter. Fisher Asset Management LLC purchased a new position in Precigen during the 4th quarter worth $29,000. Finally, Cetera Advisors LLC acquired a new stake in shares of Precigen in the 1st quarter worth $367,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.